ROIV - Roivant Sciences Ltd
IEX Last Trade
12.23
0.210 1.717%
Share volume: 4,975,512
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$12.02
0.21
1.75%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
| Report Date | 2022-08-15 | 2022-11-14 | 2023-02-13 | 2023-06-28 | 2023-08-14 | 2023-11-13 | 2024-02-13 | 2024-05-30 | |
| Total revenue | 4.319 M | 12.533 M | 17.052 M | 27.376 M | 21.624 M | 37.101 M | 37.140 M | 28.930 M | |
| Cost of revenue | 1.726 M | 3.641 M | 3.586 M | 4.175 M | 4.214 M | 3.266 M | 3.668 M | 4.412 M | |
| Gross profit | 2.593 M | 8.892 M | 13.466 M | 23.201 M | 17.410 M | 33.835 M | 33.472 M | 24.518 M | |
| 242.92% | 51.44% | 72.29% | -24.96% | 94.34% | -1.07% | -26.75% | |||
| Operating expenses | 284.902 M | 289.658 M | 293.794 M | 257.367 M | 281.323 M | 296.339 M | 320.999 M | 290.518 M | |
| Selling general and admin | 149.072 M | 157.663 M | 168.261 M | 125.510 M | 156.190 M | 164.355 M | 197.282 M | 169.616 M | |
| Research and development | 135.830 M | 131.995 M | 125.533 M | 131.857 M | 125.133 M | 131.984 M | 123.717 M | 120.902 M | |
| Total expenses | 286.628 M | 293.299 M | 297.380 M | 261.542 M | 285.537 M | 299.605 M | 324.667 M | 294.930 M | |
| 2.33% | 1.39% | -12.05% | 9.17% | 4.93% | 8.37% | -9.16% | |||
| Operating income | -282.309 M | -280.766 M | -280.328 M | -234.166 M | -263.913 M | -262.504 M | -287.527 M | -266.000 M | |
| Ebit | -282.309 M | -280.766 M | -280.328 M | -234.166 M | -263.913 M | -262.504 M | -287.527 M | -266.000 M | |
| Pretax income | -349.785 M | -313.756 M | -382.077 M | -179.216 M | -326.093 M | -327.361 M | 5.098 B | -191.453 M | |
| -10.30% | 21.78% | -53.09% | 81.96% | 0.39% | -1,657.41% | -103.76% | |||
| Income tax | 3.999 M | 2.165 M | 2.819 M | -3.793 M | 1.752 M | 3.757 M | 25.672 M | -8.957 M | |
| Net income basic | -331.809 M | -291.590 M | -352.014 M | -33.617 M | -291.816 M | -304.327 M | 5.096 B | -151.115 M | |
| 12.12% | -20.72% | 90.45% | -768.06% | -4.29% | 1,774.58% | -102.97% | |||
| Net income | -331.809 M | -291.590 M | -352.014 M | -33.617 M | -291.816 M | -304.327 M | 5.096 B | -151.115 M | |
| 12.12% | -20.72% | 90.45% | -768.06% | -4.29% | 1,774.58% | -102.97% |